QQQ   353.44 (-0.22%)
AAPL   169.95 (-1.17%)
MSFT   311.12 (-0.33%)
META   299.92 (+0.32%)
GOOGL   129.70 (+0.88%)
AMZN   124.70 (-1.02%)
TSLA   238.13 (-2.45%)
NVDA   418.57 (-0.13%)
NIO   8.34 (-0.83%)
BABA   85.72 (-0.22%)
AMD   97.49 (+1.59%)
T   14.83 (-1.26%)
F   12.33 (-0.80%)
MU   67.38 (-0.82%)
CGC   0.87 (-5.66%)
GE   111.09 (+1.06%)
DIS   79.51 (-0.67%)
AMC   7.77 (-1.77%)
PFE   32.04 (-1.11%)
PYPL   57.34 (-2.70%)
NFLX   378.47 (-0.21%)
QQQ   353.44 (-0.22%)
AAPL   169.95 (-1.17%)
MSFT   311.12 (-0.33%)
META   299.92 (+0.32%)
GOOGL   129.70 (+0.88%)
AMZN   124.70 (-1.02%)
TSLA   238.13 (-2.45%)
NVDA   418.57 (-0.13%)
NIO   8.34 (-0.83%)
BABA   85.72 (-0.22%)
AMD   97.49 (+1.59%)
T   14.83 (-1.26%)
F   12.33 (-0.80%)
MU   67.38 (-0.82%)
CGC   0.87 (-5.66%)
GE   111.09 (+1.06%)
DIS   79.51 (-0.67%)
AMC   7.77 (-1.77%)
PFE   32.04 (-1.11%)
PYPL   57.34 (-2.70%)
NFLX   378.47 (-0.21%)
QQQ   353.44 (-0.22%)
AAPL   169.95 (-1.17%)
MSFT   311.12 (-0.33%)
META   299.92 (+0.32%)
GOOGL   129.70 (+0.88%)
AMZN   124.70 (-1.02%)
TSLA   238.13 (-2.45%)
NVDA   418.57 (-0.13%)
NIO   8.34 (-0.83%)
BABA   85.72 (-0.22%)
AMD   97.49 (+1.59%)
T   14.83 (-1.26%)
F   12.33 (-0.80%)
MU   67.38 (-0.82%)
CGC   0.87 (-5.66%)
GE   111.09 (+1.06%)
DIS   79.51 (-0.67%)
AMC   7.77 (-1.77%)
PFE   32.04 (-1.11%)
PYPL   57.34 (-2.70%)
NFLX   378.47 (-0.21%)
QQQ   353.44 (-0.22%)
AAPL   169.95 (-1.17%)
MSFT   311.12 (-0.33%)
META   299.92 (+0.32%)
GOOGL   129.70 (+0.88%)
AMZN   124.70 (-1.02%)
TSLA   238.13 (-2.45%)
NVDA   418.57 (-0.13%)
NIO   8.34 (-0.83%)
BABA   85.72 (-0.22%)
AMD   97.49 (+1.59%)
T   14.83 (-1.26%)
F   12.33 (-0.80%)
MU   67.38 (-0.82%)
CGC   0.87 (-5.66%)
GE   111.09 (+1.06%)
DIS   79.51 (-0.67%)
AMC   7.77 (-1.77%)
PFE   32.04 (-1.11%)
PYPL   57.34 (-2.70%)
NFLX   378.47 (-0.21%)
NASDAQ:NUVL

Nuvalent (NUVL) Stock Forecast, Price & News

$44.54
+2.46 (+5.85%)
(As of 12:51 PM ET)
Compare
Today's Range
$43.72
▼
$45.06
50-Day Range
$41.11
▼
$49.85
52-Week Range
$17.65
▼
$50.58
Volume
141,251 shs
Average Volume
282,748 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Nuvalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
15.5% Upside
$51.33 Price Target
Short Interest
Bearish
19.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Nuvalent in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.12) to ($2.76) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

769th out of 963 stocks

Pharmaceutical Preparations Industry

358th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

NUVL stock logo

About Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Price History

NUVL Stock News Headlines

September 27, 2023 | americanbankingnews.com
Nuvalent (NASDAQ:NUVL) Research Coverage Started at Stifel Nicolaus
September 18, 2023 | markets.businessinsider.com
Nuvalent (NUVL) Receives a Buy from Piper Sandler
September 27, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 18, 2023 | finance.yahoo.com
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
September 10, 2023 | finance.yahoo.com
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
September 5, 2023 | finance.yahoo.com
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
August 31, 2023 | finance.yahoo.com
Nuvalent to Participate in Upcoming September Investor Conferences
August 10, 2023 | finanznachrichten.de
Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
September 27, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 10, 2023 | finance.yahoo.com
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
August 8, 2023 | msn.com
SVB Leerink Initiates Coverage of Nuvalent Inc - (NUVL) with Market Perform Recommendation
August 8, 2023 | markets.businessinsider.com
Expert Ratings for Nuvalent
August 1, 2023 | finance.yahoo.com
Nuvalent to Participate in Upcoming August Investor Conferences
July 25, 2023 | msn.com
Guggenheim Initiates Coverage of Nuvalent Inc - (NUVL) with Buy Recommendation
July 21, 2023 | finance.yahoo.com
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
July 6, 2023 | msn.com
Nuvalent Inc - (NUVL) Price Target Increased by 6.95% to 51.00
June 7, 2023 | finance.yahoo.com
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
May 25, 2023 | msn.com
Nuvalent: Good Medicine, But Futuristic Valuation
May 24, 2023 | finance.yahoo.com
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 12, 2023 | msn.com
Nuvalent: Q1 Earnings Insights
May 11, 2023 | finance.yahoo.com
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
April 19, 2023 | finance.yahoo.com
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023 | finance.yahoo.com
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023
April 5, 2023 | nasdaq.com
Nuvalent Breaks Below 200-Day Moving Average - Notable for NUVL
April 2, 2023 | finance.yahoo.com
Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business
March 23, 2023 | finance.yahoo.com
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
March 17, 2023 | markets.businessinsider.com
BMO Capital Keeps Their Buy Rating on Nuvalent (NUVL)
See More Headlines
Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

NUVL Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NUVL
CUSIP
N/A
CIK
1861560
Web
www.nuvalent.com
Phone
857-357-7000
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.60
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-81,850,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-25.59%
Return on Assets
-24.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.01
Quick Ratio
21.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.59 per share
Price / Book
4.39

Miscellaneous

Outstanding Shares
57,030,000
Free Float
48,602,000
Market Cap
$2.40 billion
Optionable
Not Optionable
Beta
1.35
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. James R. Porter Ph.D. (Age 47)
    CEO, Pres & Director
    Comp: $998.02k
  • Prof. Matthew D. Shair Ph.D. (Age 54)
    Founder, Head of Scientific Advisory Board & Director
    Comp: $235k
  • Ms. Alex Balcom CPA (Age 38)
    M.B.A., CFO & Treasurer
    Comp: $654.22k
  • Dr. Christopher D. Turner M.D. (Age 54)
    Chief Medical Officer
    Comp: $714.26k
  • Dr. Benjamin Lane
    Sr. VP of Technical Operations
  • Ms. Deborah Ann Miller J.D. (Age 47)
    Ph.D., Chief Legal Officer & Sec.
  • Mr. Matthew Metivier
    VP of HR
  • Ms. Darlene Noci (Age 46)
    Chief Devel. Officer
  • Mr. Henry Pelish Ph.D.
    Sr. VP of Drug Discovery
  • Mr. John Soglia Ph.D.
    Sr. VP of Translational Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NUVL Stock - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings or view top-rated stocks.

What is Nuvalent's stock price forecast for 2023?

7 analysts have issued 12 month price objectives for Nuvalent's shares. Their NUVL share price forecasts range from $42.00 to $56.00. On average, they anticipate the company's share price to reach $48.60 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts.

How have NUVL shares performed in 2023?

Nuvalent's stock was trading at $29.78 at the beginning of the year. Since then, NUVL stock has increased by 41.3% and is now trading at $42.08.
View the best growth stocks for 2023 here.

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our NUVL earnings forecast.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.04.

What ETFs hold Nuvalent's stock?

ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS).

When did Nuvalent IPO?

(NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share.

What is Nuvalent's stock symbol?

Nuvalent trades on the NASDAQ under the ticker symbol "NUVL."

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.22%), Perceptive Advisors LLC (3.86%), Driehaus Capital Management LLC (2.54%), State Street Corp (2.06%), Commodore Capital LP (2.02%) and Geode Capital Management LLC (0.93%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvalent's stock price today?

One share of NUVL stock can currently be purchased for approximately $42.08.

How much money does Nuvalent make?

Nuvalent (NASDAQ:NUVL) has a market capitalization of $2.40 billion. The company earns $-81,850,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How can I contact Nuvalent?

The official website for the company is www.nuvalent.com. The company can be reached via phone at 857-357-7000 or via email at ir@nuvalent.com.

This page (NASDAQ:NUVL) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -